NCT03360162 (VELHOR) is a clinical trial in Horton Disease, sponsored by University Hospital, Brest.

Who is sponsoring NCT03360162?

NCT03360162 is sponsored by University Hospital, Brest.

What condition does NCT03360162 study?

NCT03360162 studies Horton Disease.

Is NCT03360162 still recruiting?

NCT03360162 is currently completed. Last updated 21 April 2020.

Last reviewed 2020-04-21 · How we verify

NCT03360162: VELHOR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Velocimetric Study of Temporal Arteries in Patients With Horton Disease Using Scan-Doppler

Completed Last updated 21 April 2020

What this trial tests

trial in Horton Disease in 46 participants. Completed in 10 December 2017.

Timeline

2 November 2017

Primary endpoint
10 December 2017

10 December 2017

Quick facts

Lead sponsor	University Hospital, Brest
Status	Completed
Study type	OBSERVATIONAL
Enrollment	46
Start date	2 November 2017
Primary completion	10 December 2017
Estimated completion	10 December 2017
Sites	1 location across France

Conditions studied

Horton Disease — all drugs for Horton Disease →

Sponsor

University Hospital, Brest

Who can join

55 and older, any sex, with Horton Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The use of ultrasonography in detecting giant cell arteritis ( GCA) is emerging. Currently, temporal biopsy is the gold standard to diagnose GCA but studies have shown the interest to use B mode ultrasonography. However, until now, the study of velocities in GCA have not been yet performed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Hospital, Brest trials

Trials by the same sponsor.

NCT07526688 — Aerobic Physical Activity and Orofacial Myofascial Pain · NA · not yet recruiting
NCT07487155 — Unified Junction of Care, Integrated Treatments and Team Coordination for ADHD in Prison Settings With Substance Use Dis · NA · not yet recruiting
NCT07417605 — Diagnostic Performance Of 4D Dynamic LAFOV FDG-PET Acquisition for Differentiation of Residual Disease and Post-radiatio · not yet recruiting
NCT07302074 — Understanding of Rare Inflammatory Arthritis in Comparison to Classical Inflammatory Arthritis : Tissular Observations a · NA · recruiting
NCT06441773 — Impact of Respiratory Rehabilitation on Quality of Life in Patients With Metastatic Non-small Cell Lung Cancer Treated W · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03360162 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Brest
Last refreshed: 21 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03360162.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing